Cancer Biology

$15,066P30FY2012CANIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 39574895 Paper 39534431 Paper 39506045 Paper 39378093 Paper 39257774 Paper 39179931 Paper 39163262 Paper 39132489 Paper 39042439 Paper 38997156 Paper 38996463 Paper 38987048 Paper 38968138 Paper 38838737 Paper 38810650 Paper 38746193 Paper 38563850 Paper 38496616 Paper 38496500 Paper 38408498 Paper 38387457 Paper 38278150 Paper 38273211 Paper 38262408 Paper 38260330 Paper 38200310 Paper 38154193 Paper 38096469 Paper 37963187 Paper 37917579 Paper 37882771 Paper 37812494 Paper 37743567 Paper 37667254 Paper 37662553 Paper 37534980 Paper 37532139 Paper 37527449 Paper 37398193 Paper 37244414 Paper 37196642 Paper 37184546 Paper 37162847 Paper 36999999 Paper 36993756 Paper 36813894 Paper 36747642 Paper 36734849 Paper 36729432 Paper 36729074 Paper 36719070 Paper 36717409 Paper 36711732 Paper 36701540 Paper 36652552 Paper 36640300 Paper 36635501 Paper 36624348 Trial NCT05220254 Trial NCT03733210 Trial NCT03405142 Trial NCT03241940 Trial NCT03179449 Trial NCT02855086 Trial NCT02805075 Trial NCT02762266 Trial NCT02736578 Trial NCT02735356 Trial NCT02699723 Trial NCT02695628 Trial NCT02690948 Trial NCT02683824 Trial NCT02635074 Trial NCT02624518 Trial NCT02599194 Trial NCT02581787 Trial NCT02488070 Trial NCT02440308 Trial NCT02432118 Trial NCT02429804 Trial NCT02415608 Trial NCT02401347 Trial NCT02215928 Trial NCT02210858 Trial NCT02203565 Trial NCT02184533 Trial NCT02175745 Trial NCT02166983 Trial NCT02058550 Trial NCT02030405 Trial NCT02019069 Trial NCT01977677 Trial NCT01943188 Trial NCT01928030 Trial NCT01926990 Trial NCT01908166 Trial NCT01904643 Trial NCT01898403 Trial NCT01893892 Trial NCT01868503

Abstract

The Program in Cancer Biology is focused on investigations into mechanisms and signaling pathways involved in the malignant transformation of cells. The goals are to advance basic understanding of cancer pathogenesis and to translate basic science discoveries into the clinical arena to improve the outcome of patients with cancer. The Program encompasses three major thematic groups: 1) Mechanisms and Pathways of Oncogenesis; 2) Cell Cycle, Cytoskeleton and Genomic Stability; and 3) Epithelial Neoplasia (including skin, prostate and lung cancer subgroups). Investigations are focused on mechanistic studies of oncogenes and tumor suppressor genes, the control of cell division, genomic stability and DNA damage checkpoints, as well as disease-specific interests in hematologic malignancies, skin, prostate and lung cancers. The 40 investigators represent two different schools (the School of Medicine and the School of Humanities & Sciences), 16 Departments, and five Divisions within the Department of Medicine. The research activities of the 40 investigators are supported by 73 peer-reviewed, investigator-initiated grants (R01s and others), and five T32 training awards. Total NCI support is $4.3 million, other NIH support is $7.2 million, and non-NIH support is $3.2 million. Since 2005, program investigators have published over 400 manuscripts relevant to cancer biology in peer-reviewed journals. The Cancer Center will continue to be invaluable in assisting with the translation of the basic science findings from this Program into new clinical approaches for the diagnosis and treatment of patients with cancer.

View original record on NIH RePORTER →